PharmaEngine (4162) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.011x

Based on the latest financial reports, PharmaEngine (4162) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.01 Million ≈ $1.67 Million USD) by net assets (NT$4.79 Billion ≈ $151.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can PharmaEngine fund operations to measure how many days the company can operate on defensive assets alone.

PharmaEngine - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how PharmaEngine's cash flow conversion efficiency has evolved over time, based on yearly financial data.

PharmaEngine Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PharmaEngine ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Praetorian Acquisition Corp. Class A Ordinary Shares NASDAQ:PTOR	N/A
Deutsche Real Estate AG F:DRE2	0.004x
E-Lead Electronic Co Ltd TW:2497	-0.020x
Aldel Financial II Inc. Class A Ordinary Shares NASDAQ:ALDF	0.010x
Berry Petroleum Corp NASDAQ:BRY	0.087x
Ihlas Haber Ajansi AS IS:IHAAS	-0.228x
AGILYX ASA NK -02 F:5NQ	N/A
EUWAX Aktiengesellschaft F:EUX	0.005x

Annual Cash Flow Conversion Efficiency for PharmaEngine (2009–2024)

The table below shows the annual cash flow conversion efficiency of PharmaEngine from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see market value of PharmaEngine.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$5.40 Billion ≈ $170.12 Million	NT$456.73 Million ≈ $14.39 Million	0.085x	+27.15%
2023-12-31	NT$3.86 Billion ≈ $121.70 Million	NT$256.97 Million ≈ $8.10 Million	0.067x	+27.51%
2022-12-31	NT$3.87 Billion ≈ $121.99 Million	NT$202.01 Million ≈ $6.36 Million	0.052x	-77.90%
2021-12-31	NT$3.94 Billion ≈ $124.09 Million	NT$929.67 Million ≈ $29.29 Million	0.236x	+1361.78%
2020-12-31	NT$4.01 Billion ≈ $126.37 Million	NT$64.77 Million ≈ $2.04 Million	0.016x	+249.80%
2019-12-31	NT$3.48 Billion ≈ $109.73 Million	NT$16.08 Million ≈ $506.55K	0.005x	-97.71%
2018-12-31	NT$3.69 Billion ≈ $116.38 Million	NT$745.23 Million ≈ $23.48 Million	0.202x	+332.53%
2017-12-31	NT$3.91 Billion ≈ $123.22 Million	NT$-339.30 Million ≈ $-10.69 Million	-0.087x	-137.86%
2016-12-31	NT$3.80 Billion ≈ $119.68 Million	NT$870.38 Million ≈ $27.42 Million	0.229x	+61.57%
2015-12-31	NT$3.16 Billion ≈ $99.53 Million	NT$447.99 Million ≈ $14.11 Million	0.142x	+216.59%
2014-12-31	NT$2.93 Billion ≈ $92.20 Million	NT$131.09 Million ≈ $4.13 Million	0.045x	+357.03%
2013-12-31	NT$2.72 Billion ≈ $85.63 Million	NT$-47.37 Million ≈ $-1.49 Million	-0.017x	-141.46%
2012-12-31	NT$1.63 Billion ≈ $51.45 Million	NT$68.64 Million ≈ $2.16 Million	0.042x	-90.56%
2011-12-31	NT$618.48 Million ≈ $19.49 Million	NT$275.49 Million ≈ $8.68 Million	0.445x	+163.34%
2010-12-31	NT$81.42 Million ≈ $2.57 Million	NT$-57.26 Million ≈ $-1.80 Million	-0.703x	+91.23%
2009-12-31	NT$11.29 Million ≈ $355.76K	NT$-90.54 Million ≈ $-2.85 Million	-8.018x	--

About PharmaEngine

TWO:4162 Taiwan Biotechnology

Market Cap

$253.09 Million

NT$8.03 Billion TWD

Market Cap Rank

#15694 Global

#737 in Taiwan

Share Price

NT$56.70

Change (1 day)

+0.35%

52-Week Range

NT$53.00 - NT$79.70

All Time High

NT$178.54